Predictive Oncology

04/24/2023

We were fortunate to have had Shannon Perrine from WTAE, Pittsburgh's Action News Four, visit Predictive Oncology to learn more about how we are using Artificial Intelligence to expedite drug discovery in our ongoing fight against cancer. The segment, which will air in May, promises to cast a new light on how a Pittsburgh company is making a meaningful difference in the development of cancer drugs on a global scale.

WTAE-TV Pittsburgh GMA News

03/08/2023

At Predictive Oncology, we know there is a cancer patient waiting for therapies to be developed, hoping for a new and effective treatment to get into the hands of the clinician that can help improve their quality of life, extend their life or even cure their cancer. In honor of International Women’s Day, we would like to thank the women at Predictive Oncology who work tirelessly to bring that hope to cancer patients.

03/07/2023

More than AI: The proof of concept study we conducted at Predictive Oncology demonstrates our ability to move molecules forward with high-confidence predictions using our proprietary PEDAL platform that goes beyond machine learning and incorporates wet lab experiments from our biobank, with the domain expertise from our scientists and data from our AI.
https://hubs.la/Q01FJ_KS0

The proof of concept study we conducted at Predictive Oncology demonstrates our ability to move molecules forward with high-confidence predictions using our ...

02/28/2023

Proactive Investor’s Natalie Stoberman met with Raymond F. Vennare, CEO of Predictive Oncology, and Javier Torres-Roca, MD, Co-Founder and CEO of Cvergenx, Inc., to discuss their strategic partnership to create the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.

You can view the interview here and learn more about how this powerful collaboration will leverage Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities with the Cvergenx precision genomics radiation therapy platform.



https://www.proactiveinvestors.com/companies/news/1007431/predictive-oncology-partners-with-cvergenx-to-create-new-genomics-based-a-i-radiation-therapy-1007431.html

Predictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share their new partnership to develop the first-ever...

02/24/2023

In this "Chalk Talk Jim" podcast with James Jordan, Dr. Pamela Bush, Chief Business Officer at Predictive Oncology, talks about her work connecting science and business to advance the discovery and development of drugs against cancer. She explains how the company’s PEDAL platform can predict response for a specific drug-tumor pairing and shares how her experience prepared her for this new role.



https://outcomesrocket.health/predictive-oncology/2023/02/

Pam Bush talks about advancing the development of drugs against cancer assisted by predictive AI, ML technology, and a library of tumor samples.

02/23/2023

Predictive Oncology is pleased to announce that we have signed an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery.

By applying Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities (PEDAL), and the Cvergenx precision genomics radiation therapy platform (pGRTTM), the two companies will pursue ways in which to optimize radiotherapy (RT) to improve patient outcomes in a way that has never been done before.

More than one million patients are treated with radiotherapy every year in the US. If the overall survival of RT-treated patients is improved by 4%, that would translate into 40,000 lives, almost equivalent to eradicating breast cancer. We believe this knowledge can improve the clinical outcome of patients treated with radiotherapy.

The pGRT platform is currently being evaluated in a Phase 2 prospective clinical trial for triple negative breast cancer (NCT05528133) at the Moffitt Cancer Center. Cvergenx is a spin-out of the Moffitt Cancer Center.

Learn more about the news here:
https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-and-cvergenx-announce-partnership-develop-0

Moffitt Cancer Center

02/22/2023

Predictive Oncology welcomes FluGen to our growing family of partners. FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases. The company’s lead candidate M2SR stimulates mucosal, humoral, and cellular immunity and protection against infection and illness across seven years of virus drift. M2SR induces a durable antibody response and has shown activity as a vaccine vector for other respiratory vaccines and infectious diseases, including a COVID-19/flu combination.

02/21/2023

If you work for an academic or research institution and are involved in oncology drug discovery, we invite you to apply to the Predictive Oncology ACE program that we launched today.

Our company created ACE (Accelerating Compound Exploration) to grant early-stage academic drug development groups and technology transfer offices access to our PEDAL platform. PEDAL pairs active machine learning with an extensive biobank of 150K privately held tumor samples and in vitro assay results to help evaluate drug compounds and enable more informed selection of drug-tumor type combinations.

The deadline for the first round of applications is March 31.

https://hubs.la/Q01D0b8s0

ACE program Introducing the Predictive Oncology ACE program Welcome to the ACE (Accelerating Compound Exploration) program, an initiative we are launching at Predictive Oncology to help academic and research institutions to advance their drug discovery. Our company created ACE to grant early-stage a...

02/17/2023

Proactive Investors sat down to talk with Dr. Pamela Bush about her appointment as Chief Business Officer and the vision she brings to the company in this new role.



https://hubs.la/Q01CNbVW0

Predictive Oncology Chief Business Officer Dr. Pamela Bush joins Natalie Stoberman from the Proactive studio to share her plans for her new role with the...

02/16/2023

“The ability to use the PEDAL platform and testing in actual tumor samples to determine the drug response of these tumors is going to be…invaluable to drug discovery teams,” Pamela Bush, Ph.D., MBA, Chief Business Officer, Predictive Oncology.
https://hubs.la/Q01CCXZW0

The ability to use the PEDAL platform and testing in actual tumor samples to determine the drug response of these tumors is going to be invaluable to drug di...

02/14/2023

Precision Oncology News highlighted Predictive Oncology’s pursuit of partnerships with biopharma companies to “provide early insights that sponsors can use to prioritize drugs for development and identify biomarker-informed indications.” Read more here:
https://hubs.la/Q01Clc6C0

As appeared in Precision Oncology News. NEW YORK – Predictive Oncology wants to ink more partnerships with biopharmaceutical companies and demonstrate the ability of its commercially available PEDAL platform to provide early insights that sponsors can use to prioritize drugs for development and id...

02/04/2023

Today is World Cancer Day.

Someone at this very moment is being told that they have cancer. It will stun them. It will frighten them. It will take their breath away. It is because of them, and for them, that World Cancer Day exists--a day that was created to raise awareness about the prevention, detection and treatment of cancer.

Every single day that we walk through the doors of Predictive Oncology, we are committed to working together to give cancer patients hope. Whether this means helping biopharma companies discover new molecules, find new compounds or enable them to discover more effective ways to repurpose drugs — we exist to make that happen.

At the end of the day, we know very well that there are cancer patients waiting for therapies to be developed. To extend their lives. To improve their lives. Maybe even save their lives. This is our vision. This is our mission. This is the hope that we provide.

World Cancer Day is every day behind the doors of Predictive Oncology.

02/03/2023

We are pleased to share that Pamela Bush, Ph.D., MBA, has been appointed Chief Business Officer. In this role, she will be leading all business development, partnering and growth strategies for Predictive Oncology.

As a key member of the executive team, Dr. Bush will be spearheading the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. This includes leveraging and expanding the company’s portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company’s biopharma partners.

She previously served as Senior Vice President of Strategic Sales and Business Development at Predictive Oncology and has been instrumental in guiding the company’s strategic direction, expanding our product offerings and launching commercialization efforts for our flagship technology platform.
https://hubs.la/Q01BbY_m0

02/01/2023

We are excited to share that we are solidifying our footprint and expanding our CLIA laboratory and center for artificial intelligence in Pittsburgh --- a nearly 20,000-foot facility of prime commercial property in the hub for life sciences and robotics.

#

desiree@alschulerpr.com, 412-535-5701 RIDC Tenant Predictive Oncology Inc. Extends Lease in Lawrenceville, A Hub for Life Sciences and Robotics The Chocolate …

01/31/2023

Learn how pharmaceutical companies can accelerate drug discovery and advance drug development by pairing the artificial intelligence of our PEDAL platform with features derived from the company’s extensive biobank of more than 150,000 tumor samples. Investors are invited to meet with our Chief Executive Officer, Raymond F. Vennare, at BIO CEO for partnering sessions at the conference in NY Feb. 6-7. Please email us at partner@predictive-oncology.com to schedule a meeting.
https://hubs.la/Q01zPd3m0

Accelerate drug discovery with artificial intelligence that is paired with real tumor samples from patients from the world’s largest biobank for oncology dru...

01/19/2023

Proactive interview focuses on impact that new tool will have in oncology drug discovery

Predictive Oncology CEO Raymond Vennare and Dr. Robert Murphy, an inventor of the engine behind our artificial intelligence (AI) platform and new member of our Scientific Advisory Board, were featured in an interview with Natalie Stoberman from Proactive. They discuss the impact that Predictive Oncology has in oncology drug discovery. Predictive Oncology is the only company that can pair AI with the largest privately held biobank of 150K tumor samples covering 137 cancer types.

https://www.proactiveinvestors.com/companies/news/1003833/predictive-oncology-appoints-computational-biology-pioneer-to-scientific-advisory-board-1003833.html

Predictive Oncology CEO Raymond Vennare joins Natalie Stoberman from the Proactive newsroom to share the appointment of Dr. Bob Murphy to the...

01/11/2023

Learn about our powerful tool for oncology drug developers: Our PEDAL platform pairs AI with the world's largest tumor biobank to confidently predict drug-tumor pairings. And if you’re a pharmaceutical company at the J.P. Morgan Healthcare Conference, we still have time to meet while our CEO and SVP are in San Francisco. Email us at connect@predictive-oncology.com to connect.

https://hubs.la/Q01xK9_B0

Imagine…what if we could bring the human element into drug development before clinical trials. Predictive Oncology has the answer with a proprietary artifici...

01/10/2023

Predictive Oncology in the news: We recently met with Precision Oncology News to share about our solutions for oncology drug discovery. Read about how we can pair AI with 150K tumor samples to help advance their molecules to medicine (or rule out the ones that won’t succeed), among our other products and services. Note that you can access the free option to read the article by scrolling down to "Register for free content" and providing your name and email address.

https://hubs.ly/Q01xpwYh0

And if you are in San Francisco and are interested in learning about how this solution can help your drug discovery efforts, please email us at connect@predictive-oncology.com.

The company is hoping that biopharma partners will use its PeDAL platform to design clinical trials and get early insights into which molecules they should advance.